Top

Strahlentherapie und Onkologie

Published in:

01-03-2017 | Review Article

Specific toxicity after stereotactic body radiation therapy to the central chest

A comprehensive review

Authors: Feras Oskan, Prof. Dr. med Gerd Becker, Prof. Dr. med Martin Bleif

Published in: Strahlentherapie und Onkologie | Issue 3/2017

Abstract

The toxicity of stereotactic body radiation therapy in the central chest remains an unsettled issue. The collected data concerning the observed complications are poorly understood and are limited in their quantity and quality, thus hampering a precise delineation of treatment-specific toxicity. The majority of complications scored as toxicity grade 5, namely respiratory failure and fatal hemoptysis, are most likely related to multiple competing risks and occurred at different dose fractionation schemas, e. g., 10–12 fractions of 4–5 Gy, 5 fractions of 10 Gy, 3 fractions of 20–22 Gy, and 1 fraction of 15–30 Gy. Further investigations with longer follow-up and more details of patients’ pretreatment and tumor characteristics are required. Furthermore, satisfactory documentation of complications and details of dosimetric parameters, as well as limitation of the wide range of possible fractionation schemes is also warranted for a better understanding of the risk factors relevant for macroscopic damage to the serially organized anatomic structure within the central chest.

Available only for authorised users

Bezjak A, Paulus R, Gaspar LE et al (2016) Primary study endpoint analysis for NRG Oncology/RTOG 0813 trial of stereotactic body radiation therapy (SBRT) for centrally located non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 94:4–5CrossRef

Shanne DH, Nestle U, Allgäuer M et al (2015) Stereotactic body radiotherapy for centrally located stage I NSCLC: a multicenter analysis. Strahlenther Onkol 191:125–132CrossRef

Kang KH, Okoze CC, Patel RB et al (2015) Complications from stereotactic body radiotherapy for lung cancer. Cancers (Basel) 7:981–1004CrossRef

Evans DJ, Gomez DR, Chang JY et al (2013) Cardiac 18F-fluorodeoxyglucose uptake on positron emission tomography after thoracic stereotactic body radiation therapy. Radiother Oncol 109:82–88CrossRefPubMed

Timmerman R, Papiez L, McGary R et al (2003) Extracranial stereotactic radioablation: results of phase I study in medically inoperable stage I non-small cell lung cancer. Chest 124:1946–1955CrossRefPubMed

McGarry R, Papiez L, Williams M et al (2005) Stereotactic body radiation therapy of early stage lung non-small cell carcinoma: phase I study. J Radiat Oncol Biol Phys 63:1010–1015CrossRef

Timmerman R, Lohr F (2005) Normal tissue dose constraints applied in lung stereotactic body radiation therapy. In: Kavanagh BD, Timmerman R (eds) Stereotactic body radiation therapy. Lippincott Williams & Wilkins, Philadelphia, pp 29–37

Timmerman R, McGarry R, Yiannoutsos C et al (2006) Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early stage lung cancer. J Clin Oncol 24:4833–4839CrossRefPubMed

Milano MT, Chen Y, Katz AW et al (2009) Central thoracic lesions treated with hypofractionated stereotactic body radiotherapy. Radiother Oncol 91:301–306CrossRefPubMed

10.

Baba F, Shibamoto Y, Ogino H et al (2010) Clinical outcomes of stereotactic body radiotherapy for stage I non-small cell lung cancer using different doses dependent on tumor size. Radiat Oncol 5:81CrossRefPubMedPubMedCentral

11.

Shibamato Y, Hashizume C, Baba F et al (2012) Stereotactic body radiotherapy using a radiobiolgy-based regimen for stage I non-small cell lung cancer. Cancer 118:2078–2084CrossRef

12.

Chang JY, Li QQ, Xu QY et al (2014) Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of non-small cell lung cancer: how to fly in a “No Fly Zone”. Int J Radiat Oncol Biol Phys 88:1120–1128CrossRefPubMed

13.

Modh A, Rimmer A, Williams E et al (2014) Local control and toxicity in a large cohort of central lung tumors treated with stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 90:1168–1176CrossRefPubMedPubMedCentral

14.

Bonomo P, Livi L, Rampini A et al (2013) Stereotactic body radiotherapy for cardiac and paracardiac metastases: University of Florence experience. Radiol Med 118:1055–1065CrossRefPubMed

15.

Fakiris A, McGarry R, Yinnoutoss C et al (2009) Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four years results of a prospective phase II study. Int J Radiat Oncol Biol Phys 75:677–682CrossRef

16.

Rowe BP, Boffa DJ, Wilson LD et al (2010) Stereotactic body radiotherapy for central lung tumors. J Thorac Oncol 7:1349–1399

17.

Unger K, Ju A, Oermann E et al (2010) CyberKnife for hilar lung tumors: report of clinical response and toxicity. J Hematol Oncol 3:39CrossRefPubMedPubMedCentral

18.

Stauder MC, McDonald OK, Olivier KR et al (2011) Early pulmonary toicity following lung stereotactic body radiation therapy delivered in consecutive daily fractions. Radiother Oncol 99:166CrossRefPubMed

19.

Tekatli H, Senan S, Dahele M et al (2015) Stereotactic ablative radiotherapy (SABR) for central lung tumors: Plan quality and long-term clinical outcomes. Radiother Oncol 117:64–70CrossRefPubMed

20.

Joyner M, Salter JB, Papanikolaus N et al (2006) Stereotactic body radiation therpy for centrally located lung lesions. Acta Oncol 45:802–807CrossRefPubMed

21.

Oskan F, Korhuber C, Krause G et al (2013) Simultaneous stereotactic body radiation therapy of a primary non-small cell lung cancer and synchronous carcinoma in situ in a medically inoperable patient: case report. Radiat Oncol 8:213CrossRefPubMedPubMedCentral

22.

Onishi H, Araki T, Shirato H et al (2004) Stereotactic hypofractionated hig-dose irradiation for stage I non-small cell lung carcinoma: Clinical outcomes in 245 subjects in a Japanese multi-institutional study. Cancer 101:1623–1631CrossRefPubMed

23.

Peulen H, Karlsson K, Lindberg K et al (2011) Toxicity after reirradiation of pulmonary tumours with stereotactic body radiotherapy. Radiother Oncol 101:260–266CrossRefPubMed

24.

Song DY, Benedict SH, Cardinale RM et al (2005) Stereotactic body radiation therapy of lung tumors: preliminary experience using normal tissue complication probability-based dose limits. Am J Clin Oncol 28:591–596CrossRefPubMed

25.

Baumann P, Nyman J, Lax I et al (2006) Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries. Acta Oncol 45:787–795CrossRefPubMed

26.

Song SY, Choi W, Shin S et al (2009) Fractionated stereotactic body radiation therapy for medically inoperable stage I lung cancer adjacent to central large bronchus. Lung Cancer 66:89–93CrossRefPubMed

27.

Oshiro Y, Aruga T, Tsuboi K et al (2010) Stereotactic body radiotherapy for lung tumors at the pulmonary hilum. Strahlenther Onkol 186:274–279CrossRefPubMed

28.

Andratschke N, Zimmermann F, Boehm E et al (2011) Stereotactic radiotherapy for of histologically proven inoperable stage I non-small cell cancer: patterns of failure. Radiother Oncol 101:245–249CrossRefPubMed

29.

Bral S, Gevarte T, Linthout N et al (2011) Prospective, risk-adapted strategy of stereotactic body radiation therapy for early stage non-small-cell lung cancer: results of phase II study. Int J Radiat Oncol Biol Phys 80:1343–1349CrossRefPubMed

30.

Haasbeek CJ, Laagerwaard FJ, Soltman BJ et al (2011) Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. J Thorac Oncol 6:2036–2043CrossRefPubMed

31.

Feddock J, Arnold S, Shelton B et al (2013) Stereotactic body radiation therapy can be used safely to boost residual disease in locally advanced non-small cell lung cancer: a prospective study. Int J Radiat Oncol Biol Phys 85:1325–1331CrossRefPubMed

32.

Prendergast BM, Dobelbower MC, Bonner JA, Bonner JA et al (2013) Stereotactic body radiation therapy (SBRT) for lung malignancies: preliminary toxicity resuls using a flattening filter linear accelartor operating at 2400 monitor units per minute. Radiat Oncol 8:273CrossRefPubMedPubMedCentral

33.

Karlsson K, Nyman J, Baumann P et al (2013) Retrospective cohort study of bronchial doses and radiation-induced atelectasis after stereotactic body radiation therapy of lung tumors located close to the bronchial tree. Int J Radiat Oncol Biol Phys 87:590–595CrossRefPubMed

34.

Nishimura S, Takeda A, Sanuki N et al (2014) Toxicities of organs at risk in the mediastinal and hilar regions following stereotactic body radiotherapy for centrally located lung tumors. J Thorac Oncol 9:1370–1376CrossRefPubMed

35.

Karlsson K (2006) Centrally located lung tumors treated with stereotactic body radiation therapy: student thesis. Stockholm University, Stockholm (http://www.diva-portal.org/smash/get/diva2:197881/FULLTEXT01.pdf)

36.

Han CB, Wang WL, Quint L et al (2014) Pulmonary artery invasion, high-dose radiation, and overall survival in patients with non-small cell lung cancer. Int J Radiat Oncol Biol Phys 89:313–321CrossRefPubMedPubMedCentral

37.

Feddock J, Cleary R, Arnold S et al (2013) Risk for fatal pulmonary hemorrhage does not appear to be increased following dose escalation using stereotactic body radiotherapy (SBRT) in locally advanced non-small cell lung cancer (NSCLC). J Radiosurg SBRT 2:235–242

38.

Chang JY, Xu Q, Balter P et al (2013) Clinical outcome and toxicity in central located or isolated recurrent non-small cell lung cancer treated with stereotactic ablative radiation therapy. Int J Radiat Oncol Biol Phys 87:514–S515CrossRef

39.

Ito M, Niho S, Nihei K et al (2012) Risk factors associated with fatal pulmonary hemorrhage in locally advanced non-small cell lung cancer treated with chemoradiotherapy. BMC Cancer 12:27CrossRefPubMedPubMedCentral

40.

Kim YH, Kim EY, Ban HY et al (2010) Risk of fatal hemoptysis after concurrent chemoradiation in patients with non-small cell cancer. Chonnam Med J 46:19–24CrossRef

41.

Reck M, Barlesi F, Crino L et al (2012) Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC in patients treated with bevacizumab: a consensus report from a panel of experts. Ann Oncol 23:1111–1120CrossRefPubMed

42.

Haseltine JM, Rimmner A, Gelblum DY et al (2015) Fatal complications after stereotactic body radiation therapy for central lung tumors abutting the proximal bronchial tree. Pract Radiat Oncol 6(2):e27–e33CrossRefPubMedPubMedCentral

43.

Wulf J, Hadinger U, Oppitz U et al (2001) Stereotactic radiotherapy of targets in the lung and the liver. Strahlenther Onkol 177:645–655CrossRefPubMed

44.

Fink AS, Kim JA, McBride RD (2007) Toxicity and efficacy of treating mediastinal and hilar lesions. In: Urshel HJ (ed) Robotic radiosurgery: treating tumors that move with respiration. Springer, Heidelberg, pp 177–192CrossRef

45.

Le QT, Loo BW, Ho A et al (2006) Results of a phase I dose-escalation study using single-fraction stereotactic radiotherapy for lung tumors. J Thorac Oncol 1:802–809CrossRefPubMed

46.

Trovo M, Minatel E, Durofil E et al (2014) Stereotactic body radiation therapy for re-irradiation of persistent or recurrent non-small cell lung cancer. Int J Radiat Oncol Biol Phys 88:114–119CrossRef

47.

Kilburn JM, Kuremskz JG, Blackstock AW et al (2014) Thoracic re-irradiation using stereotactic body radiotherapy (SBRT) techniques as first or second course of treatment. Radiother Oncol 110:505–510CrossRefPubMedPubMedCentral

48.

Park HS, Harder EM, Mancini BR (2015) Central versus peripheral tumor location: influence on survival, local control and toxicity following stereotactic body radiotherapy for primary non-small cell lung cancer. J Thorac Oncol 10:832–837CrossRefPubMed

49.

Corradetti MN, Haas AR, Rengan R (2012) Central-airway necrosis after stereotactic body radiation therapy. N Eng J Med 366:2327–2329CrossRef

50.

Stephans KL, Djemil T, Diaconu C et al (2014) Esophageal dose tolerance to hypofractionated stereotactic body radiation therapy: risk factors for late toxicity. Int J Radiat Oncol Biol Phys 90:197–102CrossRefPubMed

51.

Dodds WY, Stewart ET, Hodges D et al (1973) Movement of the feline esophagus associated with respiration and peristalsis: an evaluation using tantalum marker. J Clin Invest 52:1–13.CrossRefPubMedPubMedCentral

52.

Onimaru R, Shirato H, Schimizu H et al (2003) Tolerance of organs at risk in small volume, hypofractionated, image-guided radiotherapy for primary and metastatic lung cancers. Int J Radiat Oncol Biol Phys 56:126–135CrossRefPubMed

53.

Guckenberger M, Wulf J, Mueller G et al (2009) Dose-response relationship for image-guided stereotactic body radiotherapy of pulmonary tumors: relevance of 4D dose calculation. Int J Radiat Oncol Biol Phys 74:47–54CrossRefPubMed

54.

Kelly P, Balter PA, Rebueno N et al (2010) Stereotactic body radiation therapy for patients with lung cancer previously treated with thoracic radiation. Int J Radiat Oncol Biol Phys 78:1387–1393CrossRefPubMedPubMedCentral

Title: Specific toxicity after stereotactic body radiation therapy to the central chest
A comprehensive review
Authors: Feras Oskan
Prof. Dr. med Gerd Becker
Prof. Dr. med Martin Bleif
Publication date: 01-03-2017
Publisher: Springer Berlin Heidelberg
Published in: Strahlentherapie und Onkologie / Issue 3/2017
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-016-1063-z

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Specific toxicity after stereotactic body radiation therapy to the central chest

A comprehensive review

Abstract

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2017

Fractionated vs. single-fraction stereotactic radiotherapy in patients with vestibular schwannoma

Substantieller Vorteil durch CT-geplante HDR-Brachytherapie bei Zervixkarzinompatientinnen im Vergleich zu historischen Serien bezüglich lokaler Kontrolle und Toxizität?

Stereotactic radiotherapy of vestibular schwannoma

Comparison of prostate positioning guided by three-dimensional transperineal ultrasound and cone beam CT

Einfluss von Dosis und Fraktionierung auf die kurativ intendierte Strahlentherapie nicht-kleinzelliger Bronchialkarzinome

Predictors for occlusion of cerebral AVMs following radiation therapy